AGÕæÈ˹ٷ½

STOCK TITAN

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

FibroGen (NASDAQ: FGEN) has received a crucial regulatory approval from the China State Administration for Market Regulation for the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited. This approval marks a significant milestone in the transaction that was initially announced on February 20, 2025.

The deal remains subject to other contractual closing conditions and deliverables, with the transaction expected to close in the third quarter of 2025.

FibroGen (NASDAQ: FGEN) ha ottenuto un'approvazione normativa fondamentale dalla China State Administration for Market Regulation per la cessione di FibroGen International (Hong Kong) Ltd. a AstraZeneca Treasury Limited. Questo via libera rappresenta una tappa importante per l'operazione annunciata il 20 febbraio 2025.

L'accordo resta soggetto ad altre condizioni contrattuali e obblighi da adempiere; la chiusura della transazione ¨¨ prevista per il terzo trimestre del 2025.

FibroGen (NASDAQ: FGEN) ha obtenido una aprobaci¨®n regulatoria clave por parte de la China State Administration for Market Regulation para la venta de FibroGen International (Hong Kong) Ltd. a AstraZeneca Treasury Limited. Esta autorizaci¨®n supone un hito importante en la operaci¨®n anunciada el 20 de febrero de 2025.

El acuerdo sigue sujeto a otras condiciones contractuales y requisitos por cumplir, y se espera que la transacci¨®n se cierre en el tercer trimestre de 2025.

FibroGen (NASDAQ: FGEN)?(?) AstraZeneca Treasury Limited? ?? FibroGen International (Hong Kong) Ltd. ??? ?? China State Administration for Market Regulation? ??? ?? ??? ?????. ? ???? 2025? 2? 20?? ??? ??? ?? ??? ??? ???????.

? ??? ??? ?? ??? ?? ?? ? ?? ??? ??? ??? ??, ??? 2025? 3??? ???? ??? ?????.

FibroGen (NASDAQ: FGEN) a obtenu une approbation r¨¦glementaire essentielle de la China State Administration for Market Regulation pour la vente de FibroGen International (Hong Kong) Ltd. ¨¤ AstraZeneca Treasury Limited. Cette approbation constitue une ¨¦tape importante dans l'op¨¦ration annonc¨¦e le 20 f¨¦vrier 2025.

L'accord reste soumis ¨¤ d'autres conditions contractuelles et obligations ¨¤ remplir ; la cl?ture de la transaction est pr¨¦vue au troisi¨¨me trimestre 2025.

FibroGen (NASDAQ: FGEN) hat eine wichtige beh?rdliche Genehmigung von der China State Administration for Market Regulation f¨¹r den Verkauf von FibroGen International (Hong Kong) Ltd. an AstraZeneca Treasury Limited erhalten. Diese Genehmigung stellt einen bedeutenden Meilenstein in der am 20. Februar 2025 angek¨¹ndigten Transaktion dar.

Der Vertrag bleibt weiteren vertraglichen Abschlussbedingungen und Verpflichtungen unterworfen; der Abschluss der Transaktion wird f¨¹r das dritte Quartal 2025 erwartet.

Positive
  • Received key regulatory approval from Chinese authorities for the sale
  • Transaction remains on schedule for Q3 2025 closing
Negative
  • Sale remains subject to additional closing conditions and deliverables
  • Sale of FibroGen China remains on track to close in 3Q 2025

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc.?(NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025.

The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025.

About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (°®Èð׿?, EVRENZO?) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit .

Forward-Looking Statements
This release contains forward-looking statements regarding FibroGen¡¯s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs. These forward-looking statements include, but are not limited to, statements regarding regulatory interactions, the closing of the sale of FibroGen China, and statements about FibroGen¡¯s plans and objectives. These forward-looking statements are typically identified by use of terms such as ¡°may,¡± ¡°will¡±, ¡°should,¡± ¡°on track,¡± ¡°could,¡± ¡°expect,¡± ¡°plan,¡± ¡°anticipate,¡± ¡°believe,¡± ¡°estimate,¡± ¡°predict,¡± ¡°potential,¡± ¡°continue¡± and similar words, although some forward-looking statements are expressed differently. FibroGen¡¯s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen¡¯s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
[email protected]


FAQ

What is the status of FibroGen's sale to AstraZeneca in China?

The sale has received approval from the China State Administration for Market Regulation and is expected to close in Q3 2025, subject to other closing conditions.

When did FibroGen announce the sale agreement with AstraZeneca?

FibroGen announced the Share Purchase Agreement with AstraZeneca Treasury Limited on February 20, 2025.

What regulatory approval did FGEN receive for the AstraZeneca deal?

FibroGen received approval from the China State Administration for Market Regulation for the sale of FibroGen International (Hong Kong) Ltd.

What conditions remain for the FibroGen-AstraZeneca deal to close?

The transaction remains subject to other contractual closing conditions and deliverables, though it's still on track for Q3 2025 closing.
Fibrogen Inc

NASDAQ:FGEN

FGEN Rankings

FGEN Latest News

FGEN Latest SEC Filings

FGEN Stock Data

39.93M
3.98M
1.58%
31.02%
3.7%
Biotechnology
Pharmaceutical Preparations
United States
SAN FRANCISCO